Last update at 2025-01-17T21:01:00Z
Twist Bioscience Appoints Mike Fero, Ph.D., as Chief Information Officer
Tue 15 Oct 24, 12:00 PMTwist Bioscience Achieves LEED Certification for Sustainable Operations and Maintenance
Thu 12 Sep 24, 12:00 PMTwist Bioscience Corporation (TWST): Among the Worst ARK Stocks According to Short Sellers
Sun 08 Sep 24, 07:55 PMTwist Bioscience Expands Gene Offering With Long Gene Fragments up to 5.0kb
Thu 08 Aug 24, 12:00 PM3 Healthcare AI Stocks Positioned for Potential Breakthroughs
Wed 07 Aug 24, 10:47 AMThe 3 Best Med Tech Stocks to Buy Now
Mon 05 Aug 24, 03:20 PMTwist Bioscience Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Sat 03 Aug 24, 02:16 PMTwist Bioscience Reports Fiscal Third Quarter 2024 Financial Results
Fri 02 Aug 24, 11:30 AMBreakdown | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
Income before tax | -203.46600M | -228.27400M | -154.02800M | -139.54900M | -107.37700M |
Minority interest | - | - | - | - | - |
Net income | -204.61800M | -217.86300M | -152.09800M | -139.93100M | -107.66900M |
Selling general administrative | 189.74M | 212.95M | 135.90M | 103.27M | 80.13M |
Selling and marketing expenses | - | - | - | - | - |
Gross profit | 89.73M | 84.23M | 51.71M | 28.69M | 6.96M |
Reconciled depreciation | - | 16.51M | 9.75M | 6.68M | 6.11M |
Ebit | -217.15900M | -249.02100M | -153.26000M | -117.57900M | -108.85000M |
Ebitda | -193.20500M | -247.04600M | -154.19500M | -116.26200M | -106.08300M |
Depreciation and amortization | 23.95M | 1.98M | -0.93500M | 1.32M | 2.77M |
Non operating income net other | - | 6.58M | -0.93500M | 1.32M | 2.77M |
Operating income | -217.15900M | -249.02100M | -153.26000M | -117.57900M | -108.85000M |
Other operating expenses | 452.01M | 452.59M | 285.59M | 207.68M | 163.24M |
Interest expense | 0.00500M | 0.08M | 0.37M | 0.79M | 1.29M |
Tax provision | 1.15M | -10.41100M | -1.93000M | 0.38M | 0.29M |
Interest income | 14.37M | 3.06M | 0.43M | 1.50M | 3.03M |
Net interest income | 14.36M | 2.98M | 0.07M | 0.71M | 1.74M |
Extraordinary items | - | - | - | - | - |
Non recurring | - | - | - | 22.50M | - |
Other items | - | - | - | - | - |
Income tax expense | 1.15M | -10.41100M | -1.93000M | 0.38M | 0.29M |
Total revenue | 245.11M | 203.56M | 132.33M | 90.10M | 54.38M |
Total operating expenses | 296.63M | 333.26M | 204.97M | 146.27M | 115.81M |
Cost of revenue | 155.38M | 119.33M | 80.62M | 61.41M | 47.43M |
Total other income expense net | -10.92300M | 20.75M | -0.76800M | -21.97000M | 1.47M |
Discontinued operations | - | - | - | - | - |
Net income from continuing ops | -204.61800M | -217.86300M | -152.09800M | -139.93100M | -107.66900M |
Net income applicable to common shares | - | -217.86300M | -152.09800M | -139.93100M | -107.66900M |
Preferred stock and other adjustments | - | - | - | - | - |
Breakdown | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
Total assets | 776.40M | 961.38M | 702.10M | 398.88M | 186.99M |
Intangible assets | 54.48M | 59.74M | 18.26M | 0.31M | 0.51M |
Earning assets | - | - | - | - | - |
Other current assets | 11.72M | 11.91M | 8.28M | 6.20M | 2.59M |
Total liab | 152.97M | 171.99M | 121.28M | 62.62M | 34.91M |
Total stockholder equity | 623.43M | 789.38M | 580.82M | 336.26M | 152.08M |
Deferred long term liab | - | - | - | - | - |
Other current liab | 7.80M | 53.45M | 9.62M | 2.61M | 0.82M |
Common stock | - | 789.38M | 580.82M | 336.26M | -186.99400M |
Capital stock | - | 0.00000M | 0.00000M | 0.00000M | 0.00000M |
Retained earnings | -1033.03400M | -828.41600M | -610.55300M | -458.45500M | -318.52400M |
Other liab | - | 0.06M | 5.07M | 0.35M | 0.16M |
Good will | 85.81M | 85.81M | 22.43M | 1.14M | 1.14M |
Other assets | - | -0.00100M | 49.90M | 3.40M | 4.38M |
Cash | 286.47M | 378.69M | 465.83M | 93.67M | 46.73M |
Cash and equivalents | - | - | - | - | - |
Total current liabilities | 73.32M | 90.66M | 63.05M | 36.03M | 30.35M |
Current deferred revenue | 36.57M | 3.48M | 28.76M | 18.85M | 16.44M |
Net debt | -192.40100M | -283.77500M | -402.90800M | -57.68500M | -39.00200M |
Short term debt | 14.90M | 13.64M | 9.77M | 9.74M | 3.33M |
Short long term debt | - | - | 1.55M | 3.33M | 3.33M |
Short long term debt total | 94.07M | 94.91M | 62.92M | 35.98M | 7.73M |
Other stockholder equity | 1657.22M | 1619.64M | 1190.83M | 794.63M | 283.43M |
Property plant equipment | - | 214.39M | 44.12M | 25.47M | 20.84M |
Total current assets | 424.26M | 596.48M | 546.50M | 334.87M | 160.13M |
Long term investments | - | - | - | - | - |
Net tangible assets | - | 789.38M | 540.12M | 334.82M | 150.44M |
Short term investments | 49.94M | 126.28M | 12.03M | 196.34M | 91.37M |
Net receivables | 44.06M | 40.29M | 28.55M | 26.38M | 12.10M |
Long term debt | - | - | - | 1.40M | 4.40M |
Inventory | 32.06M | 39.31M | 31.80M | 12.29M | 7.33M |
Accounts payable | 14.05M | 20.09M | 14.90M | 4.83M | 9.76M |
Total permanent equity | - | - | - | - | - |
Noncontrolling interest in consolidated entity | - | - | - | - | - |
Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
Accumulated other comprehensive income | -0.75600M | -1.84300M | 0.55M | 0.09M | 0.18M |
Additional paid in capital | - | - | - | - | - |
Common stock total equity | - | - | - | - | - |
Preferred stock total equity | - | - | - | - | - |
Retained earnings total equity | - | -828.41600M | -610.55300M | -458.45500M | -318.52400M |
Treasury stock | - | - | - | - | - |
Accumulated amortization | - | - | - | - | - |
Non currrent assets other | 8.49M | 4.96M | 9.20M | 3.40M | 4.38M |
Deferred long term asset charges | - | - | - | - | - |
Non current assets total | 352.15M | 364.89M | 155.60M | 64.01M | 26.86M |
Capital lease obligations | 94.07M | 94.91M | 61.37M | 31.25M | - |
Long term debt total | - | - | - | 1.40M | 4.40M |
Breakdown | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
Investments | - | -117.15800M | 183.70M | -104.78200M | -90.07400M |
Change to liabilities | - | 7.38M | 19.02M | -1.71100M | 12.30M |
Total cashflows from investing activities | - | -232.93000M | 156.16M | -114.65000M | -104.81000M |
Net borrowings | - | -1.55800M | -3.33300M | -3.33300M | -2.50000M |
Total cash from financing activities | 0.91M | 270.53M | 329.18M | 303.73M | 158.58M |
Change to operating activities | - | 4.42M | 3.77M | -0.44200M | 7.71M |
Net income | -204.61800M | -217.86300M | -152.09800M | -139.93100M | -107.66900M |
Change in cash | -90.97800M | -87.10000M | 373.11M | 46.85M | -34.13900M |
Begin period cash flow | 380.26M | 467.36M | 94.25M | 47.40M | 81.54M |
End period cash flow | 289.28M | 380.26M | 467.36M | 94.25M | 47.40M |
Total cash from operating activities | -142.47400M | -124.38500M | -112.24400M | -142.25500M | -87.93700M |
Issuance of capital stock | - | 269.82M | 323.86M | 295.56M | 156.21M |
Depreciation | 29.31M | 16.51M | 9.75M | 6.68M | 6.11M |
Other cashflows from investing activities | - | -13.91500M | -0.48300M | - | 0.02M |
Dividends paid | - | - | - | - | - |
Change to inventory | 7.24M | -7.53600M | -19.48900M | -4.95600M | -1.30200M |
Change to account receivables | -4.32000M | -9.62200M | -2.20200M | -14.27200M | -6.68500M |
Sale purchase of stock | -4.40500M | -7.75400M | -10.84900M | -2.42100M | 161.08M |
Other cashflows from financing activities | 5.32M | 10.02M | 19.50M | 13.92M | 4.87M |
Change to netincome | - | 82.32M | 37.10M | 17.25M | 11.59M |
Capital expenditures | 27.78M | 101.86M | 27.06M | 9.87M | 14.76M |
Change receivables | - | -9.62200M | -2.20200M | -14.27200M | -6.68500M |
Cash flows other operating | - | 10.67M | -5.00200M | -5.28000M | -1.31800M |
Exchange rate changes | - | - | - | - | - |
Cash and cash equivalents changes | - | -86.78100M | 373.09M | 46.83M | -34.16900M |
Change in working capital | 0.41M | -5.35600M | -9.38100M | -25.17600M | 3.00M |
Stock based compensation | 30.28M | 79.66M | 37.00M | 17.10M | 11.17M |
Other non cash items | 2.56M | 2.66M | 1.86M | -0.70700M | 0.52M |
Free cash flow | -170.25300M | -226.24200M | -139.30500M | -152.12300M | -102.69400M |
Sector: Healthcare Industry: Diagnostics & Research
Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
---|---|---|---|---|---|---|---|---|
TWST Twist Bioscience Corp |
1.69 3.68% | 47.56 | - | - | 6.76 | 3.01 | 5.93 | -9.0167 |
TMO Thermo Fisher Scientific Inc |
-2.06 0.37% | 559.65 | 34.71 | 23.87 | 4.62 | 4.43 | 5.29 | 20.89 |
DHR Danaher Corporation |
-3.54 1.46% | 238.36 | 29.09 | 28.01 | 5.67 | 3.20 | 6.00 | 19.09 |
IDXX IDEXX Laboratories Inc |
-9.36 2.18% | 419.26 | 49.99 | 45.66 | 11.29 | 27.85 | 11.46 | 34.46 |
IQV IQVIA Holdings Inc |
-0.3 0.15% | 197.36 | 37.82 | 19.68 | 2.76 | 7.20 | 3.61 | 17.03 |
Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
681 Gateway Boulevard, South San Francisco, CA, United States, 94080
Name | Title | Year Born |
---|---|---|
Dr. Emily Marine Leproust Ph.D. | Co-Founder, Chairman & CEO | 1973 |
Dr. Patrick John Finn Ph.D. | Pres & COO | 1972 |
Mr. James M. Thorburn | Chief Financial Officer | 1956 |
Dr. William Charles Banyai Ph.D. | Sr. VP of Advanced Devel., GM of Data Storage & Director | 1955 |
Mr. Kevin B. Yankton | VP & Chief Accounting Officer | 1967 |
Mr. Siyuan Chen | Chief Technology Officer | NA |
Dr. Aaron K. Sato Ph.D. | Chief Scientific Officer | NA |
Mr. Dennis Cho | Sr. VP, Gen. Counsel, Chief Ethics & Compliance Officer | 1971 |
Ms. Paula Green | Sr. VP of HR | 1968 |
Ms. Erin Smith | Sr. VP of Gov. Affairs & Public Policy | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.